CA2065454A1 - Use of thioredoxin in the treatment of malignantly transformed cells in animals and man - Google Patents

Use of thioredoxin in the treatment of malignantly transformed cells in animals and man

Info

Publication number
CA2065454A1
CA2065454A1 CA002065454A CA2065454A CA2065454A1 CA 2065454 A1 CA2065454 A1 CA 2065454A1 CA 002065454 A CA002065454 A CA 002065454A CA 2065454 A CA2065454 A CA 2065454A CA 2065454 A1 CA2065454 A1 CA 2065454A1
Authority
CA
Canada
Prior art keywords
thioredoxin
treatment
cells
factor
transformed cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002065454A
Other languages
English (en)
French (fr)
Inventor
Anders Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2065454A1 publication Critical patent/CA2065454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
CA002065454A 1989-09-12 1990-09-10 Use of thioredoxin in the treatment of malignantly transformed cells in animals and man Abandoned CA2065454A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903003-5 1989-09-12
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use

Publications (1)

Publication Number Publication Date
CA2065454A1 true CA2065454A1 (en) 1991-03-13

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065454A Abandoned CA2065454A1 (en) 1989-09-12 1990-09-10 Use of thioredoxin in the treatment of malignantly transformed cells in animals and man

Country Status (12)

Country Link
EP (1) EP0489113A1 (ja)
JP (1) JPH05500216A (ja)
AU (1) AU641942B2 (ja)
CA (1) CA2065454A1 (ja)
DD (1) DD298056A5 (ja)
FI (1) FI921058A0 (ja)
GR (1) GR1001151B (ja)
HU (1) HUT62932A (ja)
IE (1) IE903233A1 (ja)
PT (1) PT95284A (ja)
SE (1) SE8903003D0 (ja)
WO (1) WO1991004320A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO1998000160A1 (en) * 1996-06-28 1998-01-08 Nat Jewish Ct Immun & Respirat USE OF THIOREDOXIN-LIKE MOLECULES FOR INDUCTION OF MnSOD TO TREAT OXIDATIVE DAMAGE
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
EP0946192A1 (en) * 1996-12-06 1999-10-06 Garth Powis Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US6566514B1 (en) 1998-01-30 2003-05-20 Genesense Technologies Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
DE69939939D1 (de) 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
KR20010103655A (ko) 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2002016600A2 (en) * 2000-08-25 2002-02-28 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
WO2014145735A2 (en) 2013-03-15 2014-09-18 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (ja) * 1987-06-12 1997-07-23 味の素株式会社 ヒトａｄｆをコードする遺伝子

Also Published As

Publication number Publication date
JPH05500216A (ja) 1993-01-21
IE903233A1 (en) 1991-03-27
HUT62932A (en) 1993-06-28
FI921058A0 (fi) 1992-03-11
EP0489113A1 (en) 1992-06-10
HU9200821D0 (en) 1992-05-28
SE8903003D0 (sv) 1989-09-12
WO1991004320A1 (en) 1991-04-04
PT95284A (pt) 1991-08-14
GR900100679A (en) 1992-01-20
DD298056A5 (de) 1992-02-06
AU641942B2 (en) 1993-10-07
GR1001151B (el) 1993-05-24
AU6433690A (en) 1991-04-18

Similar Documents

Publication Publication Date Title
Rosen et al. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin
Schmouder et al. In vitro and in vivo interleukin-8 production in human renal cortical epithelia
Defrance et al. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.
Ceuppens et al. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal.
Lotz et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.
AU641942B2 (en) The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
Mrózek et al. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells
Muraguchi et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.
Roodman et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.
Schmitt et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma.
Beagley et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells.
Loughnan et al. T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells.
DeKruyff et al. Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor.
Baroja et al. Cooperation between an anti-T cell (anti-CD28) monoclonal antibody and monocyte-produced IL-6 in the induction of T cell responsiveness to IL-2.
Defrance et al. Human interferon-gamma acts as a B cell growth factor in the anti-IgM antibody co-stimulatory assay but has no direct B cell differentiation activity.
Ke et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Te Velde et al. IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes.
IE892983L (en) Mammalian t-cell growth factor
Belsito et al. Enhancement by various cytokines or 2-beta-mercaptoethanol of Ia antigen expression on Langerhans cells in skin from normal aged and young mice. Effect of cyclosporine A.
Johnson-Léger et al. Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells
EP0305468A1 (en) B-cell growth and differentiating factor BCGF 12K for use in therapy
Sleasman et al. The role of functionally distinct helper T lymphocyte subpopulations in the inductionof human B cell differentiation
Moqattash et al. Leukemia cells and the cytokine network
Willheim et al. IL-6 augments Fc IgE receptor (Fc epsilon RII/CD23) expression on human monoblastic/monocytic cell lines U937, THP-1, and Mono-Mac-6 but not on blood monocytes. Regulatory effects of IL-4 and IFN-gamma.

Legal Events

Date Code Title Description
FZDE Dead